Related Experiment Video
Updated: May 10, 2026
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
[The interpretation of immunophenotyping results during diagnostics of lymphatic proliferative disease using
Insights
Immune phenotyping reveals variations in chronic lymphatic leukemia (CLL). Lower immune phenotyping counts in CLL patients correlate with increased tumor burden, indicating disease intensity.
Area of Science:
- Hematology
- Immunology
- Oncology
Context:
- Chronic lymphatic leukemia (CLL) is a B-cell malignancy.
- Immune phenotyping is crucial for CLL diagnosis and subtyping.
- Understanding immune phenotype heterogeneity aids in predicting disease behavior.
Purpose:
- To analyze immune phenotyping heterogeneity in CLL using standard diagnostic markers.
- To correlate immune phenotypes with clinical characteristics in CLL patients.
- To investigate the relationship between immune phenotyping counts and tumor burden.
Summary:
- Analysis of 108 CLL patients revealed specific marker associations: atypical phenotypes were rarely linked to monotypic immunoglobulins and CD5, but frequently to CD23, FMC7, CD22, and CD79b.
- A subset of 10% of patients exhibited atypical immune phenotypes with "3" or "2" marker counts.
- Patients with lower immune phenotyping counts demonstrated a higher intensity of tumor substrate.
Impact:
- Identifies key immune markers for characterizing CLL heterogeneity.
- Suggests immune phenotyping counts may serve as a prognostic indicator for tumor intensity in CLL.
- Provides insights into the biological diversity of CLL for potential therapeutic strategies.
Abstract:
The article considers immune phenotyping heterogeneity of chronic lymphatic leukemia detected using basic diagnostic markers ofcell. The results of analysis of immune phenotypes of 108 patients with B-cell lymphatic proliferative diseases made it possible to establish that the atypical is related most rarely to indicators of expression of monotypic immunoglobulines and CD5 and most frequently to CD23, FMC7, CD22 and CS79b. During the present observation, the immune phenotyping count made up "3" or "2"points and the atypical alternative was registered among 10% of all examined patients with chronic lymphatic leukemia. It is demonstrated that patients with chronic lymphatic leukemia and with lower immune phenotyping count are characterized by major intensity of tumor substrate.
More Related Videos
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
06:32Multiplex Immunohistochemical Analysis of the Spatial Immune Cell Landscape of the Tumor Microenvironment
Published on: August 18, 2023